Jpmorgan Chase & CO Enzo Biochem Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Enzo Biochem Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,923 shares of ENZ stock, worth $999. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,923
Previous 1,833
4.91%
Holding current value
$999
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ENZ
# of Institutions
50Shares Held
16.6MCall Options Held
18.3KPut Options Held
0-
Harbert Fund Advisors, Inc. Birmingham, AL5.18MShares$2.69 Million1.92% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.37MShares$1.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$966,6810.0% of portfolio
-
Potomac Capital Management, Inc.1.48MShares$770,5053.63% of portfolio
-
Viex Capital Advisors, LLC Sunny Isles Beach, FL1.33MShares$693,9299.62% of portfolio
About ENZO BIOCHEM INC
- Ticker ENZ
- Exchange NYSE
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 48,720,500
- Market Cap $25.3M
- Description
- Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. Th...